PDL SP142
Alternative name:
PD-L1 SP142 FDA (TECENTRIQ®)
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
non-small cell lung cancer (NSCLC)
PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue on a VENTANA BenchMark ULTRA instrument. Evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity. Primary or metastatic NSCLC tissues may be submitted.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin,For PD-L1 SP142 evaluation, tissue submitted must have ≥50 viable tumor cells present.
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
New York Approved
YES
TAT
72 hours
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
